Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in nitric oxide donor drugs.

M R Miller1, I L Megson

  • 1Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, UK.

British Journal of Pharmacology
|April 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polyaromatic hydrocarbons in pollution: a heart-breaking matter.

The Journal of physiology·2019
Same author

Cardiovascular benefits of reducing personal exposure to traffic-related noise and particulate air pollution: A randomized crossover study in the Beijing subway system.

Indoor air·2018
Same author

Association of size-fractionated indoor particulate matter and black carbon with heart rate variability in healthy elderly women in Beijing.

Indoor air·2018
Same author

Preliminary study of hypoxia-related cardiovascular mediator-markers in patients with end-stage renal disease with and without diabetes and the effects of haemodialysis.

PloS one·2017
Same author

On the origins and genetic diversity of South American chickens: one step closer.

Animal genetics·2017
Same author

Whole-eye transplantation: a look into the past and vision for the future.

Eye (London, England)·2016
Same journal

Tangeretin ameliorates sepsis-induced neurocognitive impairment in adult male mice by suppressing Akt-driven glycolytic reprogramming and neuroinflammation.

British journal of pharmacology·2026
Same journal

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having 'bifunctional' bronchodilator and anti-inflammatory activity.

British journal of pharmacology·2026
Same journal

Glucagon-like peptide-1 improves vascular endothelial dysfunction in hypertensive mice via CREB-driven transcriptional regulation of long non-coding RNA 155383.

British journal of pharmacology·2026
Same journal

The chemokine receptor-like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling.

British journal of pharmacology·2026
Same journal

Peripheral targets for neuropathic pain.

British journal of pharmacology·2026
Same journal

Therapeutic potential of liver X receptor agonist GW3965 in preserving myelin integrity following traumatic brain injury.

British journal of pharmacology·2026
See all related articles

Nitric oxide (NO), a vital signaling molecule, offers therapeutic potential. Despite decades of research, challenges remain in developing effective NO-donor drugs for various conditions.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pharmacology
  • Medical Chemistry

Background:

  • Nitric oxide (NO) identified as a key signaling molecule in the 1980s.
  • NO has diverse physiological roles in cardiovascular, nervous, and immune systems.
  • Existing drugs like organic nitrates and sodium nitroprusside demonstrate NO's therapeutic utility.

Purpose of the Study:

  • To review recent advancements in nitric oxide (NO) donor drug development.
  • To discuss the challenges hindering the clinical application of NO-based therapies.
  • To explore the potential of NO as a therapeutic agent.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of research trends in NO donor drug discovery.

Related Experiment Videos

  • Synthesis of information on therapeutic challenges and opportunities.

    • Main Results:

    • Significant research efforts have been dedicated to NO-based therapeutics.
    • Novel NO-donor drug candidates are emerging.
    • Clinical translation of NO-based therapies faces persistent hurdles.

    Conclusions:

    • Despite its therapeutic promise, the development of NO-donor drugs remains challenging.
    • Further research is needed to overcome obstacles in NO-based drug delivery and efficacy.
    • The potential for NO-based treatments necessitates continued investigation into its complex biology and pharmacology.